Scagliotti, Giorgio V <br/><br/>
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.  [electronic resource] 

 -  The Lancet. Respiratory medicine  07 2019 
 - 569-580 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2213-2619 
<br/><br/><label>Standard No.: </label>10.1016/S2213-2600(19)30139-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Cisplatin--administration & dosage<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Indoles--administration & dosage<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Mesothelioma--drug therapy<br/>Mesothelioma, Malignant<br/>Middle Aged<br/>Pemetrexed--administration & dosage<br/>Pleural Neoplasms--drug therapy<br/>Progression-Free Survival